Compare Amgen, Inc. (AMGN) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Quest Diagnostics Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Quest Diagnostics Inc trades at $207.44 (market cap $22.96B). The key difference: Amgen, Inc. is far larger — about 8.5× Quest Diagnostics Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | DGX | |
|---|---|---|
Market Cap | $196.12B | $22.96B |
Sector | Health | Health |
52-Week High | $388.16 | $216.02 |
52-Week Low | $271.18 | $166.42 |
Enterprise Value | $241.41B | $28.98B |
Dividend Yield | 2.77% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Quest Diagnostics (DGX) trades at $207.44, down 0.29% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported $11.04B revenue in 2025 with a 9.08% net margin, supported by strong cash flow from operations of $1.89B. Recent news highlights expansion of oncology testing services, including New York State approval for Haystack MRD, enhancing its diagnostic portfolio.
DGX offers steady growth with a consensus price target of $226, implying 9% upside. Risks include rising debt levels and healthcare policy uncertainties, but analyst sentiment leans positive with 38% buy ratings. The stock's valuation at a P/E of 22.92 appears reasonable given its profitability and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
